Klaire L Laux1, Jennifer L Anderson1, Stephen P Bentivenga2, Joseph A McBride3,4, Alana Sterkel5,6, Eduard Matkovic5, Gregory M Gauthier3, Jennifer K Meece7. 1. Integrated Research and Development Laboratory, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI 54449. 2. Department of Biology, University of Wisconsin Oshkosh, Oshkosh, WI 54901. 3. Division of Infectious Disease, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792. 4. Division of Infectious Disease, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792. 5. Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792. 6. Communicable Disease Division, Wisconsin State Laboratory of Hygiene, Madison, WI 53792. 7. Integrated Research and Development Laboratory, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI 54449 meece.jennifer@marshfieldresearch.org.
Abstract
INTRODUCTION: Blastomycosis is endemic in Wisconsin with Blastomyces dermatitidis and B. gilchristii responsible for infections. Urine antigen testing is a non-invasive diagnostic method for blastomycosis with up to 93% test sensitivity. However, the test's sensitivity has not been evaluated with relationship to B. gilchristii infections. METHODS: We aimed to assess physician use of the urine antigen assay and its sensitivity to B. gilchristii and B. dermatitidis infections in a retrospective study. Culture confirmed clinical cases of blastomycosis from 2008-2016 were identified within Marshfield Clinic Health System (MCHS) and UW Hospital and Clinics (UWHC) medical records. Clinical data were abstracted from each medical record and included the following: patient demographics, presence of immune compromising and underlying medical conditions, treatment drugs, presence of isolated pulmonary or disseminated disease, death, urine antigen testing, timeframe of testing, and quantitative test values (EIA units or ng/mL). RESULTS: A total of 140 blastomycosis cases were included in this study, with MCHS contributing 114 cases to the study and UWHC contributing 26 cases. The majority of UWHC cases (n=22; 85%) were caused by B. dermatitidis and the majority of MCHS cases (n=73; 64%) were caused by B. gilchristii. UWHC physicians were significantly more likely to treat with multiple drugs during the course of infection and were more likely to prescribe amphotericin B and voriconazole. Urine antigen testing was more frequently used at UWHC (n=24; 92%) than MCHS (n=51; 45%; P < 0.00001). In this study, the urine antigen assay demonstrated 79% sensitivity. Sensitivity was significantly associated with the timeframe of testing (P < 0.05), with most true positive urine antigen tests (83%) being performed ≤ 7 days from diagnosis. In this study, the urine antigen assay was capable of detecting both B. dermatitidis and B. gilchristii at about equal sensitivity. Urine antigen concentration (ng/mL) trended higher in B. dermatitidis infections. CONCLUSION: This study found that the urine antigen assay is capable of detecting both species of Blastomyces at about the same sensitivity. We recommend continued use of the urine antigen assay for diagnosis of blastomycosis and recommend that the assay be used early in the diagnostic process to minimize the chance of false negative results.
INTRODUCTION:Blastomycosis is endemic in Wisconsin with Blastomyces dermatitidis and B. gilchristii responsible for infections. Urine antigen testing is a non-invasive diagnostic method for blastomycosis with up to 93% test sensitivity. However, the test's sensitivity has not been evaluated with relationship to B. gilchristii infections. METHODS: We aimed to assess physician use of the urine antigen assay and its sensitivity to B. gilchristii and B. dermatitidis infections in a retrospective study. Culture confirmed clinical cases of blastomycosis from 2008-2016 were identified within Marshfield Clinic Health System (MCHS) and UW Hospital and Clinics (UWHC) medical records. Clinical data were abstracted from each medical record and included the following: patient demographics, presence of immune compromising and underlying medical conditions, treatment drugs, presence of isolated pulmonary or disseminated disease, death, urine antigen testing, timeframe of testing, and quantitative test values (EIA units or ng/mL). RESULTS: A total of 140 blastomycosis cases were included in this study, with MCHS contributing 114 cases to the study and UWHC contributing 26 cases. The majority of UWHC cases (n=22; 85%) were caused by B. dermatitidis and the majority of MCHS cases (n=73; 64%) were caused by B. gilchristii. UWHC physicians were significantly more likely to treat with multiple drugs during the course of infection and were more likely to prescribe amphotericin B and voriconazole. Urine antigen testing was more frequently used at UWHC (n=24; 92%) than MCHS (n=51; 45%; P < 0.00001). In this study, the urine antigen assay demonstrated 79% sensitivity. Sensitivity was significantly associated with the timeframe of testing (P < 0.05), with most true positive urine antigen tests (83%) being performed ≤ 7 days from diagnosis. In this study, the urine antigen assay was capable of detecting both B. dermatitidis and B. gilchristii at about equal sensitivity. Urine antigen concentration (ng/mL) trended higher in B. dermatitidis infections. CONCLUSION: This study found that the urine antigen assay is capable of detecting both species of Blastomyces at about the same sensitivity. We recommend continued use of the urine antigen assay for diagnosis of blastomycosis and recommend that the assay be used early in the diagnostic process to minimize the chance of false negative results.
Authors: Patricia Connolly; Chadi A Hage; J Ryan Bariola; Eric Bensadoun; Mark Rodgers; Robert W Bradsher; L Joseph Wheat Journal: Clin Vaccine Immunol Date: 2011-11-23
Authors: Jennifer K Meece; Jennifer L Anderson; Sarah Gruszka; Brian L Sloss; Bradley Sullivan; Kurt D Reed Journal: J Infect Dis Date: 2012-12-10 Impact factor: 5.226
Authors: W Graham Carlos; Anthony S Rose; L Joseph Wheat; Steven Norris; George A Sarosi; Kenneth S Knox; Chadi A Hage Journal: Chest Date: 2010-06-17 Impact factor: 9.410
Authors: Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Elizabeth M Brown; Lisa R McTaggart; Sean X Zhang; Donald E Low; David A Stevens; Susan E Richardson Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240
Authors: Holly M Frost; Jennifer L Anderson; Lynn Ivacic; Brian L Sloss; John Embil; Jennifer K Meece Journal: BMC Infect Dis Date: 2016-09-23 Impact factor: 3.090